Acadia drug fails mid-stage study in Alzheimer's psychosis, leading to modified Phase 3
Acadia Pharmaceuticals reported a Phase 2 failure in Alzheimer’s disease psychosis, but the company said it saw enough signal to continue forward into Phase 3 — with a caveat. The biotech’s experimental ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.